Neoplasms

All Conditions

Carcinoma

TRX-818 capsules

Anthony W Tolcher, M.D., FRCP(C)

Nehal Lakhani, M.D., Ph.D.

TRX-818 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. TRX-818 is a potent anti-cancer agent in numerous human cancer cell lines. The objectives of this study are to determine the safety profile of TRX-818 including identification of dose limiting toxicity (DLT) and maximum tolerated dose (MTD) and determine the recommended dose and regimen(s) to initiate Phase 2.

A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer

A Phase I Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer

Toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0.

The MTD will be defined as the dose level at which at most one of six patients experiences a DLT after 28 days of treatment have occurred, with the next higher dose having at least 2/3 or 2/6 patients experiencing a DLT.

AUC(0-last): area under the plasma concentration versus time curve to the time of the last measurable concentration; Cmax: maximum plasma concentration; Tmax: time to maximum plasma concentration; T(1/2): terminal elimination half-life

TaiRx, Inc.

Digestive System Diseases

Rare Diseases

Stomach Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Stomach Cancer

Antineoplastic Agents

All Drugs and Chemicals

Capecitabine

Cisplatin

Cediranib

Antimetabolites

Protein Kinase Inhibitors

Enzyme Inhibitors

Cediranib 20mg + Cisplatin + Capecitabine

Given orally at a dose of 20mg/day everyday until the patient meets any discontinuation criterion.

Given as a intravenous infusion at a dose of 80mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.

Given orally at a dose of 80 - 120mg/day according to BSA for 3 weeks followed by a 2-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.

60mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.

Given orally at a dose of 1000mg/m2 twice daily for 2 weeks followed by a 1-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.

Narikazu Boku, MD

The primary objective of the study is to assess the safety and tolerability of cediranib in combination with Cisplatin plus a Fluoropyrimidine (Capecitabine or S-1) in Japanese patients with previously untreated locally advanced or metastatic unresectable gastric cancer (GC).

Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients

A Phase I, Open-label, Non-randomized Study, to Assess the Safety and Tolerability of Cediranib (AZD2171) in Combination With Cisplatin Plus a Fluoropyrimidine (Capecitabine or S-1) in Japanese Patients With Previously Untreated Locally Advanced or Metastatic Unresectable Gastric Cancer

AstraZeneca

LY3537982

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

Ying Cheng

Jianying Zhou

Xinmin Yu

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

This is an open-label, single-arm, multicenter, Phase 1 study of LY3537982 as monotherapy in Chinese participants with KRAS G12C-mutant advanced solid tumors. The main purpose of this study is to determine how much of LY3537982 gets into the bloodstream and how long it takes the body to eliminate it in Chinese participants. The safety, tolerability and preliminary efficacy of LY3537982 will also be evaluated. Approximately 12 patients will be enrolled in this study.

A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors

An Open-label, Single-arm, Multicenter, Phase 1 Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Antitumor Activity of LY3537982 in Chinese Patients With KRAS G12C-Mutant Advanced Solid Tumors

ORR: ORR assessed per Response Evaluation Criteria in Solid Tumors version 1.1 (RESIST v1.1).

DCR: DCR assessed per Response Evaluation Criteria in Solid Tumors version 1.1 (RESIST v1.1).

PFS: PFS assessed per Response Evaluation Criteria in Solid Tumors version 1.1 (RESIST v1.1).

Eli Lilly and Company

Blood and Lymph Conditions

Immune System Diseases

Infections

Symptoms and General Pathology

Leukemia

Leukemia, Lymphoid

Hepatitis A

Hepatitis

Hepatitis B

Leukemia, Lymphocytic, Chronic, B-Cell

Neoplasms by Histologic Type

Hematologic Diseases

Liver Diseases

Hepatitis, Viral, Human

Virus Diseases

Communicable Diseases

Enterovirus Infections

Picornaviridae Infections

RNA Virus Infections

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Blood-Borne Infections

Hepadnaviridae Infections

DNA Virus Infections

Leukemia, B-Cell

Chronic Disease

Disease Attributes

Chronic Graft Versus Host Disease

Chronic Lymphocytic Leukemia

Amino Acids

Vaccines

Acalabrutinib

Tyrosine Kinase Inhibitors

Ibrutinib

Tyrosine

Treatment naïve Chronic Lymphocytic Leukemia (CLL) or small lymphocytic lymphoma (SLL) patients will receive HEPLISAV-B (Hepatitis B Vaccine \[Recombinant \], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.

Ibrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose in patients with Chronic Lymphocytic Leukemia (CLL) or small lymphocytic lymphoma (SLL). Patients will receive HEPLISAV-B (Hepatitis B Vaccine \[Recombinant \], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.

Acalabrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose in patients with Chronic Lymphocytic Leukemia (CLL) or small lymphocytic lymphoma (SLL). Patients will receive HEPLISAV-B (Hepatitis B Vaccine \[Recombinant \], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.

HEPLISAV-B (Hepatitis B Vaccine \[Recombinant \], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.

HEPLISAV-B

Christopher MT Pleyer, M.D.

Background:

People with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) tend to get infections more easily. This is because their immune systems are weakened. Hepatitis B is a virus that can be transmitted when body fluids from an infected person enter the body of an uninfected person. This virus can be dangerous for people with leukemia and lymphoma. HEPLISAV-B is a new hepatitis B vaccine. Researchers want to see if it can protect people with CLL/SLL from getting hepatitis B.

Objective:

To learn how HEPLISAV-B works in people who have CLL or SLL.

Eligibility:

Adults 18 years and older with CLL (or SLL). They must be getting no treatment for their CLL, or getting ibrutinib or acalabrutinib for it.

Design:

This study lasts 6 months from the date of first vaccination.

Participants may be screened with:

Physical exam

Blood tests

Pregnancy test

Visit 1

Participants will get blood drawn and the study vaccine. It will be given as an injection. If they get any symptoms within 7 days of the vaccine, they will write them in a diary.

Visit 2

After 3 months, participants will come back to the NIH to get another blood draw and the second vaccine dose.

Visit 3

Participants will return 3 months after the second vaccine dose was given. They will have blood drawn.

This study aims to determine the HEPLISAV-B hepatitis B vaccine efficacy in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) lymphocytic patients that are treatment naive or receiving Bruton s-tyrosine kinase inhibitor (BTK-I) therapy. (Note: Since CLL and SLL are considered the same disease, CLL/SLL will be referred to as CLL hereafter, unless otherwise specified).

Key Eligibility Criteria:

1. Diagnosis of CLL
2. Cohort 1: Treatment naive CLL or SLL patients
3. Cohort 2: Subjects must be receiving ibrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose
4. Cohort 3: Subjects must be receiving acalabrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose
5. No known active or past hepatitis B infection
6. No history of prior hepatitis B virus vaccination (approved or investigational)
7. Age greater greater than or equal to 18 years.
8. ECOG performance status of 0-1

Design:

Patients with CLL will enroll on the study for the purpose of determining the HEPLISAV-B vaccine efficacy in patients who are treatment naive ore receiving BTK-I therapy. A series of 2 doses of HEPLISAV-B will be given on a 0- and 3- month schedule by intramuscular injection. Subjects will be followed at regular intervals and receive serologic response assessment following completion of the HEPLISAV-B vaccine series (6 months after the first vaccine

administration).

Study Objectives:

Primary Objective:

a) Determine the rate of hepatitis B seroprotective titer achievement (anti-HBs greater than or equal to 10mIU/mL) following completion of the HEPLISAV-B 2-dose vaccine series (6 months after the first vaccine administration) in the following populations:

* CLL patients who are treatment naive (n=54)
* CLL patients receiving treatment with ibrutinib (n=27)
* CLL patients receiving treatment with acalabrutinib (n=27)

Secondary Objective:

a) Determine the safety and tolerability of the HEPLISAV-B vaccine among CLL patients who are treatment naive or receiving BTK-Is (ibrutinib or acalabrutinib).

HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)

Response to the HEPLISAV-B Hepatitis B Vaccine in Treatment Naive Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's -Tyrosine Kinase Inhibitor (BTK-I)

Determine the rate of hepatitis B seroprotective titer achievement (anti-HBs 10mIU/mL) following completion of the HEPLISAV-B 2-dose vaccine series (6 months after the first vaccine administration) among chronic lymphocytic leukemia (CLL) patients who are treatment naïve or receiving Bruton Tyrosine Kinase (BTK) inhibitors (Ibrutinib or Acalabrutinib).

Determine the safety of the HEPLISAV-B vaccine among chronic lymphocytic leukemia (CLL) patients who are treatment naïve or receiving Bruton Tyrosine Kinase (BTK) inhibitors (Ibrutinib or Acalabrutinib).

Determine the tolerability of the HEPLISAV-B vaccine among chronic lymphocytic leukemia (CLL) patients who are treatment naïve or receiving Bruton Tyrosine Kinase (BTK) inhibitors (Ibrutinib or Acalabrutinib).

National Heart, Lung, and Blood Institute (NHLBI)

All events whether volunteered by the subject, discovered by study personnel during questioning, or detected through physical examination, clinically significant laboratory test, or other means will be recorded.

Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib

Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib

Chronic Lymphocytic Leukemia Patients That Are Treatment Naïve

Total

Age, Categorical

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Christopher Pleyer, M.D. Principal Investigator, NIH, NHLBI

All participants that completed the 2 doses vaccine series and blood draws. 8 participants could not complete laboratory assessments due to COVID pandemic.

Number of Participants With HEPLISAV-B Seroprotective Titer (Anti-HBs 10mIU/mL)

Number of Participants That Experienced Serious Adverse Events Following HEPLISAV-B Vaccine Among CLL Patients

Number of Participants That Did Not Complete Study Due to Intolerance of the HEPLISAV-B Vaccine Among CLL Patients.

Overall Study

Pharmaceutical Solutions

Immune Checkpoint Inhibitors

Participants will receive dose A of ASP8374 solution intravenously on day 1 of every 3-week cycle.

Participants will receive dose B of ASP8374 solution intravenously on day 1 of every 3-week cycle.

ASP8374

Global Medical Lead

The purpose of this study is to evaluate the tolerability and safety profile and to characterize the pharmacokinetic profile of ASP8374 in Japanese patients with locally advanced (unresectable) or metastatic solid tumors.

This study also evaluates the anti-tumor effect of ASP8374.

This study consists of two arms (Arm A: ASP8374 dose A; and Arm B: ASP8374 dose B). Arm B would only be opened if Arm A is deemed tolerable.

The study consists of 2 periods: Screening (up to 28 days) and treatment period. The Dose Limiting Toxicities (DLT) observation period is set at the beginning of the treatment period. A subject can continue to participate in the study after the end of the DLT observation period until discontinuation criteria are met. After discontinuation of study drug treatment, all subjects will complete an end of treatment visit and safety follow-up visits.

Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors

A Phase 1, Open Label Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors

Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."

DLT is graded using National Cancer Institute Common Toxicity Criteria for Adverse Events \[NCI-CTCAE\] Version 4.03. The DLT observation period may be increased if deemed appropriate by the Tolerability Evaluation Meeting.

An AE is any untoward medical occurrence in a subject administered a study drug, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product.

Most frequent immune-related AEs observed with currently approved checkpoint inhibitors include rash, oral mucositis, dry mouth, colitis/diarrhea, hepatitis, pneumonitis, and endocrinopathies .

An AE is considered "serious" if, in the view of either the investigator or sponsor, it results in any of the following outcomes: death, life-threatening, persistent or significant disability/incapacity or substantial disruption, congenital anomaly or birth defect, hospitalization, or medically important event

Number of patients with potentially clinically significant laboratory values.

ECGs should be obtained after the subject has rested quietly and is awake in a fully supine position (or semi-recumbent, if supine is not tolerated) for 10 minutes before the first ECG from a triplicate or single ECG. Any clinically significant adverse changes on the ECS will be reported as (serious) AEs.

Number of patients with potentially clinically significant vital sign values.

Number of patients with potentially clinically significant physical exam values.

The ECOG Scale \[Oken, 1982\] will be used to assess performance status ; 0=Fully active, able to carry on all predisease performance without restriction; 1=Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature, (e.g., light housework, office work); 2=Ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about more than 50% of waking hours; 3=Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4=Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.

AUClast: area under the concentration-time curve from the time of dosing up to the last measurable concentration. AUClast will be derived from the PK serum samples collected.

AUCinf: AUC from the time of dosing extrapolated to time infinity. AUCinf will be derived from the PK serum samples collected.

AUCinf(%extrap): Percentage of AUCinf due to extrapolation from the last measurable concentration to time infinity

AUCtau: AUC from the time of dosing to the start of the next dosing interval at multiple dose conditions. AUCtau will be derived from the PK serum samples collected.

Cmax: maximum concentration. Cmax will be derived from the PK serum samples collected.

Ctrough: trough concentration. Ctrough will be derived from the PK serum samples collected.

tmax: time of maximum concentration. Tmax will be derived from the PK serum samples collected.

t1/2: terminal elimination half-life. t1/2 will be derived from the PK serum samples collected.

tlast: time of last measurable concentration. tlast will be derived from the PK serum samples collected.

CL: total clearance after intravenous dosing. CL will be derived from the PK serum samples collected.

Vz: volume of distribution after intravenous dosing during the terminal elimination phase. will be derived from the PK serum samples collected. Vz will be derived from the PK serum samples collected.

Vss: volume of distribution at steady state after intravenous dosing. Vss will be derived from the PK serum samples collected.

Tumor size is defined as the sum of the diameters of all target lesions per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percent change from baseline in tumor size will be calculated for subjects with target lesions at baseline.

BOR is defined as the best response recorded from the start of the study treatment until the end of treatment.

Astellas Pharma Inc

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Recurrence

Urinary Bladder Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urinary Bladder Diseases

Urologic Diseases

Male Urogenital Diseases

BCG Vaccine

Ten patients with non-muscular invasive bladder cancer ≥14 days after surgery were included.

The 10 patients were infused with BCG 120mg dissolved in 40 \~ 50 mL normal saline once a week for 6 times, then once every 2 weeks for 3 times, and then once a month (30 days) for 10 times, with a total of 19 times.

BCG for therapeutic use

Jiang Sh Suan, Doctor

Ding Fan, Master

This clinical study adopted a single-arm, open, single-centertrial design. The purpose of this study was to evaluate the safety and tolerability, PK characteristics, shedding and immune response characteristics of BCG for therapeutic use developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. in patients aged 18 and over after transethral resection of non-muscular invasive bladder cancer.

This clinical study adopted a single-arm, open, single-centertrial design. The purpose of this study was to evaluate the safety and tolerability, PK characteristics, shedding and immune response characteristics of BCG for therapeutic use developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. in patients aged 18 and over after transethral resection of non-muscular invasive bladder cancer.

This study includes three stages: screening period, observation period of administration, and safety follow-up period.

Screening period:

within 28 days before the first administration, the subjects will be eligible for enrollment confirmation.

Observation period of administration:

10 patients with non-muscular invasive bladder cancer ≥ 14 days after operation were included.The 10 patients were infused with BCG 120mg once a week for 6 times, then once every 2 weeks for 3 times, and then once a month (30 days) for 10 times, with a total of 19 times.

The peripheral blood samples of the subjects were collected to evaluate the exposure and immune response characteristics of the drugs in the blood, and the urine samples were collected to examine the immune response characteristics and shedding of the drugs. The safety data of each subject were observed ,collected and recorded, including vital signs, laboratory examination, adverse event (AE) and serious adverse event (SAE) (within 7 days after the first 5 times of each infusion treatment, and within 14 days after the sixth infusion (before V8 visit)). After 14 days of follow-up after the sixth infusion of the last subject, the clinical trial Data and Safety Monitoring Board (DSMB) will conduct an interim analysis to evaluate the safety and tolerability based on the obtained data. For the AE that did not recover within 14 days after the sixth infusion, the investigators should followe up until the AE was remission, or returned to the baseline, or the subject's condition was stable, or the subject lost follow-up / death.

When the subjects continued 13 times in the later period of bladder instillation therapy; blood routine examination was performed before the 10th, 13th, 16th and 19th instillation, and blood biochemical examination was performed before the 13th and 19th instillation. Cystoscopy and urine cytology were performed at the 3rd, 6th, 9th and 12th months after the first infusion. The subjects then continued their follow-up visits..

Safety follow-up period:

Safety follow-up was performed for7 days after the last administration. For the AE that did not recover 7 days after the last administration, the investigators should follow up to AE remission, or return to the baseline, or the subject's condition was stable, or the subject lost follow-up / death.

BCG for Therapeutic Use Phase I Clinical Trial

Phase I Clinical Trial to Evaluate the Safety and Tolerability of BCG for Therapeutic Use in Preventing Postoperative Recurrence of Non-muscular Invasive Bladder Cancer in People Aged 18 and Over

1. After each infusion of the first 6 times:

   * Body temperature,

     * Blood pressure,

       * Pulse；
2. Blood routine within 12 hours after each infusion of the first 6 times;
3. Urine routine before each infusion for the first 6 times;
4. On the 14th day after the 6th infusion (before administration of V8 visit):

   * Physiacl examination,

     * Vital signs,

       * Laboratory examination,

         * 12-lead ECG examination,

           * Color ultrasound of urinary system,

             * Imaging results ,
5. All AE and SAE during 0-7 days after each infusion of the first 5 times;
6. All AE and SAE within 14 days after the end of the 6th infusion ;
7. During the 7th to 19th infusion of the experimental drug:

   * AE,

     * SAE ,

       * Tumor recurrence ,
8. Examination results of safety follow-up : including AE, SAE, physical examination, vital signs, clinical laboratory examination , 12-lead ECG examination, color ultrasound of urinary system, imaging examination and so on.

The peripheral blood of the subjects was collected within 1h before the 1st and 6th administration and 2 h±30 min、24 h±2 h after the 1st and 6th administration to evaluate the exposure of BCG for therapeutic use in the blood.

The levels of Mycobacterium tuberculosis (nucleic acid positive/negative) in the blood sample after the 1st and 6th administration were detected.

Blood sample collection: Peripheral blood samples of subjects were collected within 1 h before the 1st and 6th administration, and 2 h±30 min and 24 h±2 h after the 1st and 6th administration.

Urine sample collection: last excreted urine of subjects were collected before the 1st and 6th administration, and excreted urine of subjects were collected 2 h±1 h, 4 h±1 h, 8 h±2 h, and 24 h±3 h after 1st and 6th BCG administration .

The levels of interleukin 2 (IL-2), interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 12 (IL-12), interferon gamma (IFN- γ) and tumor necrosis factor (TNF) in blood and urine sample were detected.

The urine excreted from the subjects were collected on the 1st and 3rd day after the 1st and 6th administration , in which the urine on the first day included 2 h ±1 h, 4 h ±1 h, 8 h ±2 h and 24 h ±3 h after BCG administration, and only once on the 3rd day to investigate the drug shedding.

The levels of Mycobacterium tuberculosis (nucleic acid positive/negative) in the urine sample after the 1st and 6th administration were detected.

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Wu-Chou Su, M.D

TRX-818 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. TRX-818 is a potent anti-cancer agent in numerous human cancer cell lines. The objectives of this study are to determine the safety profile of TRX-818 including identification of dose limiting toxicity (DLT) and maximum tolerated dose (MTD) in Asians and determine the recommended dose and regimen(s) to initiate Phase 2.

Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients

A Phase I Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Solid Tumors in Asians

AUC(0-last): area under the plasma concentration versus time curve to the time of the last measurable concentration

Tmax: time to maximum plasma concentration

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer	NCT02507544	Carcinoma Advanced Cancer	TRX-818 capsule...	18 Years -	TaiRx, Inc.
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer	NCT02507544	Carcinoma Advanced Cancer	TRX-818 capsule...	18 Years -	TaiRx, Inc.
Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients	NCT00960349	Gastric Cancer	Cediranib Cisplatin S-1 Cisplatin Capecitabine	20 Years -	AstraZeneca
A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors	NCT06235983	Advanced Solid ...	LY3537982	18 Years -	Eli Lilly and Company
HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)	NCT03685708	Hepatitis Safety and Tole...	HEPLISAV-B	18 Years - 99 Years	National Institutes of Health Clinical Center (CC)
Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients	NCT00960349	Gastric Cancer	Cediranib Cisplatin S-1 Cisplatin Capecitabine	20 Years -	AstraZeneca
HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)	NCT03685708	Hepatitis Safety and Tole...	HEPLISAV-B	18 Years - 99 Years	National Institutes of Health Clinical Center (CC)
Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors	NCT03945253	Advanced Solid ...	ASP8374	20 Years -	Astellas Pharma Inc
Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors	NCT03945253	Advanced Solid ...	ASP8374	20 Years -	Astellas Pharma Inc
BCG for Therapeutic Use Phase I Clinical Trial	NCT06100653	Non-muscular In...	BCG for therape...	18 Years -	Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients	NCT02703298	Carcinoma Advanced Cancer	TRX-818 capsule...	20 Years -	TaiRx, Inc.
A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors	NCT06235983	Advanced Solid ...	LY3537982	18 Years -	Eli Lilly and Company

Spots Global Cancer Trial Database for safety and tolerability